Page 39 - Read Online

Han et al. Cancer Drug Resist 2024;7:16 Cancer
DOI: 10.20517/cdr.2024.01
Drug Resistance

Original Article Open Access

Isocucurbitacin B inhibits glioma growth through
PI3K/AKT pathways and increases glioma sensitivity

to TMZ by inhibiting hsa-mir-1286a

1
1
2
1
1,5
6
Mingyu Han 1 , Junsha An , Sui Li 1,2,3,4 , Huali Fan , Li Wang , Qing Du , Junrong Du , Yuxin Yang , Yuqin
3
Song , Fu Peng 1
1
Department of Pharmacology, Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, Sichuan
Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West
China School of Pharmacy, Sichuan University, Chengdu 610041, Sichuan, China.
2
Department of Epidemiology and Health Statistics, West China School of Public Health and West China Fourth Hospital,
Sichuan University, Chengdu 610041, Sichuan, China.
3
Integrated Traditional Chinese and Western Medicine Department, Sichuan Clinical Research Center for Cancer, Sichuan
Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and
Technology of China, Chengdu 610041, Sichuan, China.
4
Waigaoqiao Free Trade Zone, WuXi Biologics, Shanghai 214122, China.
5
Livzon Pharmaceutical Group Inc, Zhuhai 519090, Guangdong, China.
6
Chongqing Western Biomedical Technology Co. Ltd., Chongqing 400039, China.
Correspondence to: Yuxin Yang, Department of Epidemiology and Health Statistics, West China School of Public Health and
West China Fourth Hospital, Sichuan University, Chengdu 610041, Sichuan, China. E-mail: 1581023993@qq.com; Yuqin Song,
Integrated Traditional Chinese and Western Medicine Department, Sichuan Clinical Research Center for Cancer, Sichuan Cancer
Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of
China, Chengdu 610041, Sichuan, China. E-mail: 774953409@qq.com; Dr. Fu Peng, Department of Pharmacology, Key
Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, Sichuan Engineering Laboratory for Plant-
Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan
University, Chengdu 610041, Sichuan, China. E-mail: pengf@scu.edu.cn
How to cite this article: Han M, An J, Li S, Fan H, Wang L, Du Q, Du J, Yang Y, Song Y, Peng F. Isocucurbitacin B inhibits glioma
growth through PI3K/AKT pathways and increases glioma sensitivity to TMZ by inhibiting hsa-mir-1286a. Cancer Drug Resist
2024;7:16. https://dx.doi.org/10.20517/cdr.2024.01
Received: 7 Jan 2024 First Decision: 11 Mar 2024 Revised: 7 Apr 2024 Accepted: 24 Apr 2024 Published: 8 May 2024
Academic Editor: Godefridus J. Peters Copy Editor: Pei-Yun Wang Production Editor: Pei-Yun Wang

Abstract
Aim: Glioma accounts for 81% of all cancers of the nervous system cancers and presents one of the most drug-
resistant malignancies, resulting in a relatively high mortality rate. Despite extensive efforts, the complete
treatment options for glioma remain elusive. The effect of isocucurbitacin B (isocuB), a natural compound

© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0
International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing,
adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as
long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and
indicate if changes were made.

www.oaepublish.com/cdr